Results 41 to 50 of about 114,379,182 (224)

IMMUNOLOGICAL MARKERS OF DIABETES MELLITUS IN VARIOUS CLINICAL VARIANTS OF THE DISORDER

Медицинская иммунология, 2014
. We studied immune markers of diabetes mellitus, as well as their relations to clinical features at the onset of disease. The patients with newly diagnosed diabetes were examined.
G. G. Baiburina
doaj   +1 more source

Latent Autoimmune Diabetes in Adults: Current Status and New Horizons [PDF]

Endocrinology and Metabolism, 2018
Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do not necessitate insulin-therapy for at least 6 months after diagnosis are demarcated as having latent autoimmune diabetes in ...
Paolo Pozzilli, Silvia Pieralice
doaj   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

Arthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi, Roberta A. Berard, Jean‐Philippe Proulx‐Gauthier, Heinrike Schmeling, Michelle Batthish, Gilles Boire, Adam M. Huber, Dax G. Rumsey, Jaime Guzman, Gaëlle Chédeville, The CAPRI registry Investigators   +10 more
wiley   +1 more source

Small fibre neuropathy in patients with latent autoimmune diabetes in adults

, 2015
The prevalence of latent autoimmune diabetes in adults (LADA) in patients diagnosed with type 2 diabetes mellitus (T2DM) ranges from 7 to 10% (1). They present at a younger age and have a lower BMI but poorer glycemic control, which may increase the risk
Asghar, Omar, Fadavi, Hassan, Tavakoli, M, Ponirakis, Georgios, Ponirakis, Georgos, Malik, Rayaz A, Petropoulos, Ioannis, Petropoulos, Ioannis N., Efron, Nathan, Boulton, Andrew J.M., Jeziorska, Maria, Efron, N, Malik, Rayaz A., Boulton, AJM, Alam, Uazman, Asghar, O, Petropoulos, Ioannis N, Tavakoli, Mitra, Marshall, Andrew, Boulton, Andrew J M   +19 more
core   +1 more source

The system of tumor necrosis factor α in the pathogenesis of autoimmune diabetes mellitus

Бюллетень сибирской медицины, 2011
The aim of this study was to evaluate the impact of TNFα and their receptor in autoimmune diabetes. It was found the most pronounced inhibition of production of soluble forms of the receptor for TNFα in the background of an increased number of ...
T. S. Prokhorenko, T. V. Saprina, F. E. Lazarenko, N. V. Ryazantseva, I. N. Vorozhtsova, V. V. Novitsky   +5 more
doaj   +1 more source

Condition‐Associated Pattern Extraction and Recovery From Multi‐Condition Single‐Cell RNA‐seq Data With CAPER

Advanced Science, EarlyView.
Decoupling biological signals from unwanted variation in multi‑condition single‑cell RNA sequencing data remains challenging. CAPER disentangles condition‑associated biological effects from sample heterogeneity through matrix factorization, producing interpretable latent factors and a batch‑corrected expression matrix.
Ye Li, Jin Ning, An Wang, Minxi Shi, Yuanze Chen, Guoliang Liu, Shiquan Sun   +6 more
wiley   +1 more source

Latent autoimmune diabetes in adults

The Biomedical & Life Sciences Collection, 2013
Latent Autoimmune Diabetes in Adults (LADA) is the term used to describe adults who have a slowly progressive form of diabetes mellitus (DM) of autoimmune etiology, but that may be treated initially without insulin. Although it shares some immunological and genetic aspects with type 1 DM, it affects an age group that is typically affected by type 2 DM.
Felipe, Pollak, Tatiana, Vásquez
openaire   +3 more sources

Autoimmunity in latent autoimmune diabetes in adults

AIMS Medical Science, 2019
Latent autoimmune diabetes in adults (LADA) is clinically characterized by onset after age 30, absence of ketoacidosis, insulin independence for at least 6 months after diagnosis, and presence of circulating islet-cell antibodies. These include glutamic acid decarboxylase (GADA) autoantibodies, tyrosine phosphatase-2 autoantibodies, or zinc-transporter
openaire   +1 more source

A Decoy‐Receptor‐Armed Biomimetic Nanotherapeutic With Inherent Tropism for Conserved Pathogenic Macrophages for Treating Osteoarthritis and Intervertebral Disc Degeneration

Advanced Science, EarlyView.
A biomimetic doppelgänger nanosystem neutralizes extracellular inflammatory cytokines and silences intracellular pyroptosis, reprogramming pathogenic macrophages to attenuate both joint and spine degeneration. ABSTRACT Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) are debilitating musculoskeletal disorders driven by shared ...
Fudong Li, Bin Zhang, Zhiqiu Zhang, Bing Zheng, Linhui Han, Chen Yan, Jialin Li, Kaiqiang Sun, Tianyi Zhao, Jiangang Shi   +9 more
wiley   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source